March 20, 2017 / 10:38 AM / 4 months ago

BRIEF-Boehringer Ingelheim says first patient enrolled in PF-ILD trial

1 Min Read

March 20 (Reuters) - Boehringer Ingelheim:

* Says first patient has been enrolled in PF-ILD (Progressive Fibrosing Interstital Lung Disease) trial

* Boehringer Ingelheim -study investigates efficacy, safety of nintedanib in range of progressive fibrosing lung conditions other than idiopathic pulmonary fibrosis

* Boehringer Ingelheim - in total, 600 patients will be included around world in study Source text for Eikon:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below